News summarySEC EDGARNov 4, 2026, 12:00 PM
ADMA Biologics 8-K (2.02, 9.01): reported results of operations
ADMA Biologics reported third-quarter 2026 revenue of $141.1 million and net income of $49.9 million, with ASCENIV revenue up 31% to $124.7 million; it reiterated revenue guidance of at least $530 million and raised minimum adjusted net income and EBITDA outlook to $180 million and $275 million.